# This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).

> **NCT05935085** · PHASE2 · TERMINATED · sponsor: **AnaptysBio, Inc.** · enrollment: 201 (actual)

## Conditions studied

- Atopic Dermatitis Eczema

## Interventions

- **DRUG:** ANB032
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05935085
- **Lead sponsor:** AnaptysBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-06-13
- **Primary completion:** 2024-10-16
- **Final completion:** 2025-01-07
- **Target enrollment:** 201 (ACTUAL)
- **Why stopped:** ANB032 did not meet the primary endpoint in moderate-to-severe atopic dermatitis
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05935085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05935085, "This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05935085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*